Day: January 13, 2025

DRAPER, Utah, Jan. 13, 2025 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA”) custodian, today announced estimates of HSAs, HSA Assets and Total Accounts for its fiscal year ending January 31, 2025, reflecting a strong sales year with record New HSAs from Sales and strong custodial HSA Asset growth.Estimated HSAs to be approximately 9.8 million by January 31, 2025, up from 8.7 million a year earlier. Estimated HSA Assets to be approximately $31 billion, up from $25.2 billion at the end of fiscal year 2024, with approximately $17 billion of HSA Cash. Invested balances included in the estimated assets are subject to market fluctuation. Estimated Total Accounts to be approximately 17 million compared to 15.7 million at the end of fiscal...

Stuart Van Houten, Will Join BlackLine Effective February 17, 2025, and Succeed Mark Woodhams as Head of Global Sales Team BlackLine Expects Fourth Quarter and Full Year 2024 Revenue to Meet or Slightly Exceed High End of Guidance Range; Reaffirms Non-GAAP Operating Margin Guidance LOS ANGELES, Jan. 13, 2025 (GLOBE NEWSWIRE) — BlackLine, Inc. (Nasdaq: BL) (“BlackLine” or the “Company”), the future-ready platform for the Office of the CFO, today announced that Stuart Van Houten, a seasoned technology and enterprise SaaS veteran, will assume the newly created role of Chief Commercial Officer on February 17, 2025. Mr. Van Houten will be responsible for leading the Company’s global sales organization and revenue operations. He will succeed BlackLine’s current Chief Revenue Officer, Mark Woodhams, as head of the global sales team. Mr....

LAS VEGAS, Jan. 13, 2025 (GLOBE NEWSWIRE) — Galaxy Gaming, Inc. (OTC: GLXZ), the world’s largest independent developer and distributor of casino table games and technology, will showcase its innovative new table game operating system, brand-new table games, and extensive online content portfolio at this year’s ICE Barcelona 2025 taking place from January 20-22 at Stand #3N32. “ICE Barcelona is an incredible opportunity to meet with our global customers and demonstrate the full power of our product portfolio,” said Matt Reback, President and CEO of Galaxy Gaming. “Our proven table game brands continue to captivate players, while our innovative technology solutions elevate these experiences across both land-based and digital channels.” This year’s stand will feature their standout table games collection...

PLAINVIEW, N.Y, Jan. 13, 2025 (GLOBE NEWSWIRE) — Vaso Corporation (“Vaso”) (OTCQX: VASO), a leader in human capital, information technology and MedTech, today announced new executive appointments to the Vaso management team and Board of Directors, effective January 1, 2025.Jane Moen was appointed Vaso Corporation’s Chief Operating Officer. She will continue in her role as President of VasoHealthcare, a Vaso Corporation subsidiary. Ms. Moen has served as a Director of Vaso Corporation’s Board since 2020. Jonathan Newton was promoted to Chief Financial Officer of Vaso Corporation from his previous role as Vaso’s Co-Chief Financial Officer. As part of this development, Michael Beecher, previously Co-Chief Financial Officer, will transition to a Vaso financial and investor relations advisory role. Edgar Rios was elected Vice Chairman...

CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that CEO Brian Carrico has published a letter to shareholders highlighting the Company’s achievements in 2024 and vision for 2025. Dear shareholders, We are thrilled to connect with you as we celebrate NeurAxis’s remarkable achievements in 2024 and anticipate the exciting opportunities ahead. This is a pivotal time for our company as we strive to establish ourselves as an innovative leader in the gastroenterology space. Our immediate focus is on driving the growth of IB-Stim for pediatric irritable bowel syndrome (IBS) and advancing the commercialization of RED,...

Company closes 2024 with multiple award recognitions for corporate social responsibility, workplace culture, inclusion and belonging, and more BURLINGTON, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) — Progress (Nasdaq: PRGS), the trusted provider of AI-powered digital experiences and infrastructure software, today announced it has received multiple awards from prestigious organizations for its inclusive workplace, culture and focus on corporate social responsibility (CSR). Progress strives to create an environment where employees can grow to their full potential while bringing their best selves to work. The company has been acknowledged year-over-year for its people-centric approach and programs that include talent, career & leadership development, excellent benefits, its multiple employee resource groups (ERGs), and well-being...

HOUSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) — Freight Technologies, Inc. (Nasdaq: FRGT, “Fr8Tech” or the “Company”), a logistics management innovation company, offering a diverse portfolio of technology-driven solutions that address distinct challenges within the supply chain ecosystem, announced today the renewal of its logistics services contract with Kimberly-Clark de México, S.A.B. de C.V. The renewed agreement extends the relationship for an additional two years and encompasses the transportation of products and goods throughout Mexico. This renewal marks the continuation of a successful collaboration that began in 2022. Since inception, the relationship between Fr8Tech and Kimberly-Clark de México has grown steadily, with significant year-over-year increases in over-the-road (OTR) load capacity and expanded service. Currently,...

The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, or dermatologic and neurological conditions, today announced the completed safety review of the first cohort of eight healthy volunteers in the Company’s Phase 1 study of ART26.12. Progression to the next cohort marks a major milestone in the development of Fatty Acid Binding Protein (FABP) inhibitors as a novel treatment approach for a large number of potential indications. ART26.12 is the lead compound in Artelo’s proprietary...

ROUYN-NORANDA, Quebec, Jan. 13, 2025 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to report that Brunswick Exploration Inc. (TSX-V:BRW, OTCQB:BRWXF; FRANKFURT:1XQ) have announced additional lithium bearing intersections from their 12,000 metre drill program on the Mirage Property (Lac Escale portion) in the Eeyou Istchee-James Bay area of Quebec, on which Globex retains a 3% Gross Metal Royalty. Drilling focused on the Central Zone including the MR-6 and MR-3 dykes and has continued to intersect wide and well-mineralized intervals on their extensions and to depth. Highlights include:37 meters...

Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemiaAchieved in vivo editing of liver cells in non-human primates and in vivo delivery to two additional cell types in humanized miceAnticipated 2025 milestones include: declare two in vivo development candidates, one in HSCs and one in liver; present further in vivo HSC data; present in vivo data in one liver indication; establish one additional target cell type/tissue; and continue to derive revenue through sublicensing foundational IPStrategic priorities through 2027 include: submit at least one IND/CTA; achieve human in vivo proof of concept in HSC editing for the treatment of sickle cell disease and beta thalassemia; and commence...